1. Home
  2. RLMD
  3. RLMD News

Latest Relmada Therapeutics Inc. (RLMD) News on November 16, 2025

Relmada Therapeutics Inc (RLMD) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
RLMD

GuruFocus.com

3 days ago

Relmada Therapeutics Inc (RLMD) Q3 2025 Earnings Call Highlights: Strategic Advances and ...

Relmada (RLMD) Q3 2025 Earnings Call Transcript
RLMD

Motley Fool

3 days ago

Relmada (RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
RLMD

GlobeNewswire

3 days ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

When Your Investable Assets Reach This Number, It's Time To Hire A Financial Planner
RLMD

Money Digest

7 days ago

When Your Investable Assets Reach This Number, It's Time To Hire A Financial Planner

Marriott International Announces Termination of Agreement with Sonder
RLMD

CNW Group

7 days ago

Marriott International Announces Termination of Agreement with Sonder

Ways Trump Can Control Mortgage Rates
RLMD

GOBankingRates

7 days ago

Ways Trump Can Control Mortgage Rates

6 Things the 1% Are Doing With Their Roth Accounts (And Why You Should Pay Attention)
RLMD

GOBankingRates

7 days ago

6 Things the 1% Are Doing With Their Roth Accounts (And Why You Should Pay Attention)

Israel receives remains believed to be officer killed in 2014 Gaza war
RLMD

AFP

7 days ago

Israel receives remains believed to be officer killed in 2014 Gaza war

Earnings Beat: Deluxe Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
RLMD

Simply Wall St.

7 days ago

Earnings Beat: Deluxe Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Earnings Beat: Take-Two Interactive Software, Inc. (NASDAQ:TTWO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
RLMD

Simply Wall St.

7 days ago

Earnings Beat: Take-Two Interactive Software, Inc. (NASDAQ:TTWO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

My husband and I have plenty of money to retire now – should we keep working to leave our son a larger inheritance?
RLMD

24/7 Wall St.

7 days ago

My husband and I have plenty of money to retire now – should we keep working to leave our son a larger inheritance?

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
RLMD

GlobeNewswire

9 days ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

RLMD

MT Newswires

10 days ago

Relmada Therapeutics Insider Bought Shares Worth $299,200, According to a Recent SEC Filing

RLMD

MT Newswires

10 days ago

Relmada Therapeutics Insider Bought Shares Worth $599,500, According to a Recent SEC Filing

RLMD

MT Newswires

10 days ago

Relmada Therapeutics Insider Bought Shares Worth $1,100,000, According to a Recent SEC Filing

Relmada Therapeutics Leads These 3 Promising Penny Stocks
RLMD

Simply Wall St.

11 days ago

Relmada Therapeutics Leads These 3 Promising Penny Stocks

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
RLMD

GlobeNewswire

12 days ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
RLMD

GlobeNewswire

12 days ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
RLMD

GlobeNewswire

a month ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Promising Penny Stocks To Watch In October 2025
RLMD

Simply Wall St.

2 months ago

Promising Penny Stocks To Watch In October 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
RLMD

GlobeNewswire

5 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/11/2025

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/10/2025

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/09/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/30/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/29/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/28/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/27/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/23/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/22/2025

RLMD

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/21/2025

RLMD

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Relmada Therapeutics Inc Earnings Call

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ...
RLMD

GuruFocus.com

6 months ago

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ...

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
RLMD

GlobeNewswire

6 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
RLMD

GlobeNewswire

6 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

RLMD

MT Newswires

7 months ago

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

7 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

7 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

RLMD

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Relmada Therapeutics Inc Earnings Call

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...
RLMD

GuruFocus.com

8 months ago

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
RLMD

GlobeNewswire

8 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
RLMD

GlobeNewswire

8 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
RLMD

GlobeNewswire

8 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada acquires Tourette’s therapy rights from Asarina
RLMD

Pharmaceutical Technology

9 months ago

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
RLMD

GlobeNewswire

9 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

US Penny Stocks To Watch In January 2025
RLMD

Simply Wall St.

10 months ago

US Penny Stocks To Watch In January 2025

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/09/2024

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
RLMD

GlobeNewswire

a year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/06/2024

RLMD

MT Newswires

a year ago

Relmada Shares Continue Downward Spiral After Downgrades

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
RLMD

TipRanks

a year ago

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/05/2024

RLMD

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Lower Late Afternoon

RLMD

MT Newswires

a year ago

Top Midday Decliners

RLMD

MT Newswires

a year ago

Relmada Therapeutics' Late-Stage Trial of REL-1017 Deemed 'Futile' -- Shares Decline Pre-Bell

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
RLMD

GlobeNewswire

a year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/04/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/03/2024

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks
RLMD

Simply Wall St.

a year ago

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/02/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/29/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/27/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/26/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/25/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/22/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/21/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/20/2024

Relmada Therapeutics to Present at Jefferies London Healthcare Conference
RLMD

GlobeNewswire

a year ago

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/19/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/18/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/15/2024

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
RLMD

GlobeNewswire

a year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/14/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/13/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/11/2024

RLMD

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/08/2024

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
RLMD

GuruFocus.com

a year ago

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
RLMD

PR Newswire

a year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/07/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/06/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/05/2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
RLMD

GlobeNewswire

a year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/04/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/01/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/31/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/30/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/29/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/28/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/25/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/24/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/23/2024

3 US Penny Stocks To Monitor In October 2024
RLMD

Simply Wall St.

a year ago

3 US Penny Stocks To Monitor In October 2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/22/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/21/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/18/2024

RLMD

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/17/2024

Share on Social Networks: